Zolimomab aritox

Zolimomab aritox is a monoclonal antibody designed for the treatment of cancer. It was developed by Peregrine Pharmaceuticals, a biopharmaceutical company specializing in the development and manufacturing of therapeutics to treat cancer and other life-threatening diseases.

Mechanism of Action[edit | edit source]

Zolimomab aritox works by binding to the CD22 antigen on the surface of B cells, which are a type of white blood cell. The CD22 antigen is often overexpressed in certain types of cancer, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. Once bound, zolimomab aritox delivers a toxic payload to the cancer cells, causing them to die.

Clinical Trials[edit | edit source]

Zolimomab aritox has undergone several clinical trials to assess its safety and efficacy in treating cancer. In a Phase I trial, the drug was found to be well-tolerated and showed promising results in patients with refractory non-Hodgkin lymphoma. However, further development of the drug was halted due to financial constraints.

Potential Side Effects[edit | edit source]

Like all drugs, zolimomab aritox can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. Serious side effects can include anaphylaxis, a severe allergic reaction.

Future Research[edit | edit source]

While the development of zolimomab aritox has been halted, research into CD22-targeted therapies continues. These therapies hold promise for the treatment of B-cell malignancies and other diseases where the CD22 antigen is overexpressed.